← Back to Screener
Maze Therapeutics, Inc. Common Stock (MAZE)
Price$26.84
Favorite Metrics
Price vs S&P 500 (26W)-6.34%
Price vs S&P 500 (4W)-51.01%
Market Capitalization$1.40B
P/E Ratio (Annual)77.66x
All Metrics
P/CF (Annual)18.79x
Book Value / Share (Quarterly)$7.19
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.29
Price vs S&P 500 (YTD)-36.34%
EPS (TTM)$-2.07
10-Day Avg Trading Volume1.03M
EPS Excl Extra (TTM)$-2.07
EPS (Annual)$-3.05
ROI (Annual)-36.94%
Cash / Share (Quarterly)$6.93
P/E Normalized (Annual)77.66x
ROA (Last FY)-33.02%
EBITD / Share (TTM)$-2.22
Cash Flow / Share (Annual)$-2.29
P/B Ratio3.93x
P/B Ratio (Quarterly)5.62x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)13.77x
ROA (TTM)-26.28%
EPS Incl Extra (Annual)$-3.05
Current Ratio (Annual)15.50x
Quick Ratio (Quarterly)15.16x
3-Month Avg Trading Volume0.70M
52-Week Price Return243.40%
EV / Free Cash Flow (Annual)14.84x
Revenue / Employee (TTM)$0
P/S Ratio (Annual)8.34x
Asset Turnover (Annual)0.70x
52-Week High$53.65
EPS Excl Extra (Annual)$-3.05
26-Week Price Return2.41%
Quick Ratio (Annual)15.16x
13-Week Price Return-31.67%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)15.50x
Enterprise Value$1,207.069
Revenue / Employee (Annual)$0
Pretax Margin (Annual)31.88%
Cash / Share (Annual)$6.93
3-Month Return Std Dev90.19%
Net Income / Employee (TTM)$-1
ROE (Last FY)-36.94%
EPS Basic Excl Extra (Annual)$-3.05
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.07
ROI (TTM)-29.60%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)208.30%
Year-to-Date Return-32.20%
5-Day Price Return2.44%
EPS Normalized (Annual)$-3.05
Net Profit Margin (Annual)10.97%
Month-to-Date Return-5.90%
EBITD / Share (Annual)$-3.27
Operating Margin (Annual)34.38%
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.07
P/B Ratio (Annual)5.62x
Book Value / Share (Annual)$7.19
Price vs S&P 500 (13W)-34.54%
Beta0.77x
P/FCF (Annual)18.67x
Revenue / Share (TTM)$0.00
ROE (TTM)-29.60%
52-Week Low$7.16
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.33
4.33
4.33
4.33
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MAZEMaze Therapeutics, Inc. Common Stock | — | — | — | — | $26.84 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Maze Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for chronic kidney disease, cardiovascular disease, and obesity using its proprietary Compass platform. The platform identifies disease-causing genetic variants and links them to underlying biological pathways, enabling targeted therapeutic development. The company is advancing two lead programs—MZE829 and MZE782—both designed to treat chronic kidney disease.